Hiratani K, Sakito O, Mukae H, Morikawa N, Kadota J, Fukushima K, Komori K, Hirota M, Hara K
Nihon Kyobu Shikkan Gakkai Zasshi. 1989 Jun;27(6):673-8.
Sialosylated Lewisa (S-Lea) is an active antigen determinant of CA19-9 which is well known as a tumor maker. Sialosylated Lewisx (S-Lex) is a positional isomer of S-Lea. The positive percent of S-Lex and CA19-9 in pleural effusion from the patients with primary lung cancer was 49.1% and 40.0%, respectively. However, most S-Lea positive effusions showed a positive level of S-Lex. Therefore, S-Lex is considered to be more useful as a tumor marker than CA19-9. The studies on gel chromatography of the effusion obtained from a patients showed high levels of both antigens using sephacryl S-1000 revealed that the molecular weights of S-Lex and CA19-9 were more than 2 X 10(6) and the elution profile of S-Lex coincided with that of CA19-9 fractionated effusions using the monoclonal antibodies to the antigens showed the same pattern of elution profiles of these carbohydrates. From these results, we concluded that the carriers of S-Lex and CA19-9 in pleural effusion from lung cancer might be the same molecules with a high molecular weight more than 2 X 10(6).
唾液酸化路易斯a（S-Lea）是众所周知的肿瘤标志物CA19-9的活性抗原决定簇。唾液酸化路易斯x（S-Lex）是S-Lea的位置异构体。原发性肺癌患者胸腔积液中S-Lex和CA19-9的阳性率分别为49.1%和40.0%。然而，大多数S-Lea阳性积液显示S-Lex呈阳性水平。因此，S-Lex被认为比CA19-9更适合作为肿瘤标志物。对一名患者胸腔积液进行凝胶色谱分析的研究表明，使用sephacryl S-1000检测到两种抗原水平都很高，结果显示S-Lex和CA19-9的分子量超过2×10⁶，并且S-Lex的洗脱图谱与使用针对这些抗原的单克隆抗体对CA19-9进行分级分离的胸腔积液的洗脱图谱一致。从这些结果来看，我们得出结论，肺癌患者胸腔积液中S-Lex和CA19-9的载体可能是分子量超过2×10⁶的同一高分子量分子。
